Cited by 185Protein Kinase Regulation and GTPase SignalingPI3K/AKT/mTOR signaling in cancerSignaling Pathways in Disease

The DOI matches its Crossref record; 108 of the 109 references it cites were found in a registry or an index.

Bryostatin-1: A Novel PKC Inhibitor in Clinical Development

Kortmansky, Jeremy, Schwartz, Gary K.·2003·Cancer Investigation

DOI 10.1081/cnv-120025095

Open this paper in CoChat — free account

Abstract

Modulation of PKC represents a novel approach to cancer therapy. Bryostatin-1 is a macrocyclic lactone derived from a marine invertebrate that binds to the regulatory domain of protein kinase C. Short-term exposure to bryostatin-1 promotes activation of PKC, whereas prolonged exposure promotes significant downregulation of PKC. In numerous hematological and solid tumor cell lines, bryostatin-1 inhibits proliferation, induces differentiation, and promotes apoptosis. Furthermore, preclinical studies indicate that bryostatin-1 potently enhances the effect of chemotherapy. In many cases, this effect is sequence specific. Bryostatin-1 is currently in phase I and phase II clinical trials. The major toxicities are myalgias, nausea, and vomiting. Although there is minimal single-agent activity, combinations with standard chemotherapy are providing very encouraging results and indicate a new direction in cancer therapy.

Integrity signals

Registry

Crossref · 10.1081/cnv-120025095

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The extended protein kinase C superfamily
MELLOR, H., & Parker, P. J. (1998) · Biochemical Journal · doi:10.1042/bj3320281 · Cited by 1,539
Matrix metalloproteinase inhibitors
Wojtowicz‐Praga, S., Dickson, R. B., & Hawkins, M. (1997) · Investigational New Drugs · doi:10.1023/a:1005722729132 · Cited by 524
Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma
Moch, H., Gasser, T., Amin, M. B., Torhorst, J. K. H., Sauter, G., & Mihatsch, M. J. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3 · Cited by 472
A Functional Role for Mitochondrial Protein Kinase Cα in Bcl2 Phosphorylation and Suppression of Apoptosis
Ruvolo, P. P., Deng, X., Carr, B. K., & May, W. S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25436 · Cited by 452
Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.
Kraft, A. S., Smith, J. B., & Berkow, R. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.5.1334 · Cited by 257
Selective translocation of beta II-protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells.
Hocevar, B. A., & Fields, A. P. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52396-6 · Cited by 248
Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin
Hennings, H., Blumberg, P. M., Pettit, G. R., Herald, C. L., Shores, R., & Yuspa, S. H. (1987) · Carcinogenesis · doi:10.1093/carcin/8.9.1343 · Cited by 230
Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis.
May, W. S., Tyler, P. G., Ito, T., Armstrong, D. K., Qatsha, K. A., & Davidson, N. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47099-8 · Cited by 219
Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C.
Wender, P. A., CRIBBS, C. M., Koehler, K. F., Sharkey, N. A., Herald, C. L., Kamano, Y., Pettit, G. R., & Blumberg, P. M. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7197 · Cited by 201
Bryostatin and CD40‐ligand enhance apoptosis resistance and induce expression of cell survival genes in B‐cell chronic lymphocytic leukaemia
Kitada, S., Zapata, J. M., Andreeff, M., & Reed, J. C. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01642.x · Cited by 187

Show all 109 references

Research works printed but not linked: 43

Hu Z. B., 1993, Leukemia, 7, 1817
Lilly M., 1990, Cancer Res., 50, 5520
al-Katib A., 1993, Exp. Hematol., 21, 61
Kraft A. S., 1987, Oncogene, 1, 111
Drexler H. G., 1989, Blood, 74, 1747, 10.1182/blood.V74.5.1747.1747 · DOI
Wall N. R., 2000, Int. J. Mol. Med., 5, 165
Wang H., 1998, Int. J. Mol. Med., 1, 915
Gschwend J. E., 2000, Mol. Pharmacol., 57, 1224
Asiedu C., 1995, Cancer Res., 55, 3716
Koutcher J. A., 2000, Clin. Cancer Res., 6, 1498
Al-Katib A. M., 1998, Clin. Cancer Res., 4, 1305
Scala S., 1995, Clin. Cancer Res., 1, 1581
Lilly M., 1991, Leukemia, 5, 283
Berkow R. L., 1993, Cancer Res., 53, 2810
Szallasi Z., 1996, Cancer Res., 56, 2105
Schuchter L. M., 1991, Cancer Res., 51, 682
Hornung R. L., 1992, Cancer Res., 52, 101
Kennedy M. J., 1992, Cancer Res., 52, 1278
10.1097/00008390-200004000-00001 · DOI
McBain J. A., 1990, Cell Growth Differ., 1, 281
Jones R. J., 1990, Blood, 75, 1319, 10.1182/blood.V75.6.1319.1319 · DOI
Mohammad R. M., 1994, Cancer Res., 54, 165
Mohammad R. M., 1998, Clin. Cancer Res., 4, 1337
Mohammad R. M., 2000, Clin. Cancer Res., 6, 4950
Beck F. W., 2000, Int. J. Mol. Med., 5, 341
Mohammad R. M., 1999, Int. J. Oncol., 14, 945
Kaubisch A. K.D., 2000, Proc. Am. Soc. Clin. Oncol., 19, 230a
Marshall J. I.J.M., 1998, Proc. Am. Assoc. Cancer Res., 39, 601
Langevin A. M.B.M., 1998, Proc. Am. Soc. Clin. Oncol., 17, 206
Weitman S., 1999, Clin. Cancer Res., 5, 2344
Institute N. C, 1997, Fact Sheet
Grant S., 1998, Clin. Cancer Res., 4, 611
Pavlick A. C.H.A., 2001, Proc. Am. Soc. Clin. Oncol., 20, a328
Bangalore N. S.B.S., 2000, Proc. Am. Soc. Clin. Oncol., 19
Lenz H. J.G.M., 2000, Proc. Am. Soc. Clin. Oncol., 19
Dowlati A. R.K., 2000, Proc. Am. Soc. Clin. Oncol., 19
Grant S. C.L., 2000, Blood, 93, a590
Zonder J. A., 2001, Clin. Cancer Res., 7, 38
Varterasian M. L., 2000, Clin. Cancer Res., 6, 825
Ilson D. S.M., 2001, Proc. Am. Soc. Clin. Oncol., 20, a633,159
Charoentum C. M.A., 2001, Proc. Am. Soc. Clin. Oncol., 20, a2834
Tuttle T. M., 1992, Cancer Res., 52, 548
Tuttle T. M., 1993, Cancer Res., 53, 833

Sorted by citations

Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555
PKC Regulates a Farnesyl-Electrostatic Switch on K-Ras that Promotes its Association with Bcl-Xl on Mitochondria and Induces Apoptosis
Bivona, T. G., Quatela, S. E., Bodemann, B. O., Ahearn, I. M., Soskis, M. J., Mor, A., Miura, J., Wiener, H. H., Wright, L. P., Saba, S. G., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.012 · Cited by 467
Tetrahydrofuran-Containing Macrolides: A Fascinating Gift from the Deep Sea
Lorente, A., Lamariano‐Merketegi, J., Alberício, F., & Álvarez, M. (2013) · Chemical Reviews · doi:10.1021/cr3004778 · Cited by 354
Recent advances in deep-sea natural products
Skropeta, D., & Wei, L. (2014) · Natural Product Reports · doi:10.1039/c3np70118b · Cited by 238

See all 185

Bryostatin 1
McIlwain, C. (2008) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.63983-2
Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug
Zonder, J. A., & Philip, P. A. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.12.2189 · Cited by 28
Anticancer Activity of the Marine-Derived Compound Bryostatin 1: Preclinical and Clinical Evaluation
Kowalczyk, T., Staszewski, M., Markowicz-Piasecka, M., Sikora, J., Amaro, C., Picot, L., & Sitarek, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167765 · Cited by 8
The clinical development of the bryostatins
Clamp, A. R., & Jayson, G. C. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200208000-00001 · Cited by 82
Bryostatin 1, A New Anti-tumor Agent: From Bench to Bedside
Mohammad, R. M., Raza, S. A., Maki, A., & Al-Katib, A. (1996) · Journal of the Islamic Medical Association of North America · doi:10.5915/28-1-6175
Differential Effect of Bryostatin 1 and Phorbol 12-Myristate 13-Acetate on HOP-92 Cell Proliferation Is Mediated by Down-regulation of Protein Kinase Cδ
Choi, S. H., Hyman, T., & Blumberg, P. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4177 · Cited by 32
Phase I Study of Prolonged Infusion Bryostatin-1 in Patients
Marshall, J. L., Bangalore, N. S., El‐Ashry, D., Fuxman, Y., Johnson, M. D., Norris, B. D., Oberst, M. D., Ness, E. A., Wojtowicz‐Praga, S., Bhargava, P., et al. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.4.17 · Cited by 30
Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1
Prendiville, J., McGown, A. T., Gescher, A. J., Dickson, A. J., Courage, C., Pettit, G. R., Crowther, D., & Fox, B. W. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.353 · Cited by 9
The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szállási, Z., Du, L., Levine, R., Lewin, N. E., Nguyen, P. N., Williams, M. D., Pettit, G. R., & Blumberg, P. M. (1996) · PubMed · Cited by 51
Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant, S., Roberts, J. D., Poplin, E. A., Tombes, M. B., Kyle, B., Welch, D. G., Carr, M. A., & Bear, H. D. (1998) · PubMed · Cited by 51

Authors: Kortmansky, J., & Schwartz, G. K.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Kortmansky, Jeremy
Schwartz, Gary K.
Venue: Cancer Investigation
Publisher: Informa UK Limited
Published: 2003-01
Volume: 21
Issue: 6
Pages: 924-936
ISSN: 0735-7907 (ISSN-L)
1532-4192
DOI: 10.1081/cnv-120025095
OpenAlex: W1996339149
Cited by: 183
References: 109
Citations by year: 2026: 5 · 2025: 10 · 2024: 5 · 2023: 2 · 2022: 8 · 2021: 7 · 2020: 8 · 2019: 6 · 2018: 3 · 2017: 12 · 2016: 9 · 2015: 7 · 2014: 13 · 2013: 4 · 2012: 12
FWCI: 2.07
Type: journal article
Language: en
Open access: closed
Locations: Cancer Investigation (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (R01CA67819, CA09207, R01CA067819, T32CA009207)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords: bryostatin 1, protein kinase C, PKC inhibitors, macrocyclic lactones, marine natural products, cancer therapy, chemosensitization, apoptosis, cell differentiation, hematologic malignancies, solid tumors, drug toxicity, clinical trials
MeSH terms: Antineoplastic Agents, Cell Differentiation, Humans, Lactones, Nausea, Pain, Protein Kinase C, Vomiting, Down-Regulation, Apoptosis, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Macrolides, Bryostatins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bryostatin-1: A Novel PKC Inhibitor in Clinical Development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks